| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
The proliferation of the breast cancer cell lines MCF7, T47D, HS578T, and MDA-MB-468 is inhibited by oxyphenisatinacetate. In estrogen receptor (ER)-positive MCF7 and T47D cells, obenidine acetate triggered TNFα production and TNFR1 degradation, indicating the presence of autocrine receptor-mediated death in these cell lines. Autophagy and mitochondrial malfunction are the outcomes of 10 micromoles per liter of orbenidine acetate treatment [1].
|
|---|---|
| ln Vivo |
TNFR1 degradation and eIF2α phosphorylation were observed in conjunction with intraperitoneal administration of oxyphenisatinacetate (300 mg/kg) to suppress tumor growth in the MCF7 xenograft model [1].
|
| References |
[1]. Morrison BL, et al. Oxyphenisatin acetate (NSC 59687) triggers a cell starvation response leading to autophagy, mitochondrial dysfunction, and autocrine TNFα-mediated apoptosis. Cancer Med. 2013 Oct;2(5):687-700
|
| Additional Infomation |
Oxyphenisatine acetate is a member of phenols and a benzoate ester.
Oxyphenisatin acetate is the pro-drug of [oxyphenisatin] (3,3-bis(4-hydroxyphenyl)-1H-indol-2-one). The FDA withdrew its approval for the use of oxyphenisatin acetate due to safety reasons. A laxative that undergoes enterohepatic circulation. It may cause jaundice. |
| Molecular Formula |
C24H19NO5
|
|---|---|
| Molecular Weight |
401.42
|
| Exact Mass |
401.126
|
| CAS # |
115-33-3
|
| Related CAS # |
Oxyphenisatine;125-13-3
|
| PubChem CID |
8269
|
| Appearance |
White to off-white solid powder
|
| Density |
1.282 g/cm3
|
| Boiling Point |
566.5ºC at 760 mmHg
|
| Melting Point |
244℃
|
| Flash Point |
296.4ºC
|
| Vapour Pressure |
7.5E-13mmHg at 25°C
|
| Index of Refraction |
1.611
|
| LogP |
3.961
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
625
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1NC2=C(C=CC=C2)C1(C3=CC=C(OC(C)=O)C=C3)C4=CC=C(OC(C)=O)C=C4
|
| InChi Key |
PHPUXYRXPHEJDF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H19NO5/c1-15(26)29-19-11-7-17(8-12-19)24(18-9-13-20(14-10-18)30-16(2)27)21-5-3-4-6-22(21)25-23(24)28/h3-14H,1-2H3,(H,25,28)
|
| Chemical Name |
[4-[3-(4-acetyloxyphenyl)-2-oxo-1H-indol-3-yl]phenyl] acetate
|
| Synonyms |
NSC-117186; NSC 117186; Acetophenolisatin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~62.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (6.23 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (2.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4912 mL | 12.4558 mL | 24.9116 mL | |
| 5 mM | 0.4982 mL | 2.4912 mL | 4.9823 mL | |
| 10 mM | 0.2491 mL | 1.2456 mL | 2.4912 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
